全文获取类型
收费全文 | 3343篇 |
免费 | 254篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 50篇 |
儿科学 | 92篇 |
妇产科学 | 93篇 |
基础医学 | 470篇 |
口腔科学 | 44篇 |
临床医学 | 313篇 |
内科学 | 779篇 |
皮肤病学 | 81篇 |
神经病学 | 386篇 |
特种医学 | 92篇 |
外科学 | 316篇 |
综合类 | 20篇 |
一般理论 | 1篇 |
预防医学 | 286篇 |
眼科学 | 91篇 |
药学 | 177篇 |
中国医学 | 5篇 |
肿瘤学 | 315篇 |
出版年
2024年 | 6篇 |
2023年 | 55篇 |
2022年 | 109篇 |
2021年 | 228篇 |
2020年 | 95篇 |
2019年 | 134篇 |
2018年 | 151篇 |
2017年 | 107篇 |
2016年 | 105篇 |
2015年 | 115篇 |
2014年 | 169篇 |
2013年 | 182篇 |
2012年 | 272篇 |
2011年 | 301篇 |
2010年 | 143篇 |
2009年 | 133篇 |
2008年 | 210篇 |
2007年 | 225篇 |
2006年 | 201篇 |
2005年 | 167篇 |
2004年 | 146篇 |
2003年 | 113篇 |
2002年 | 110篇 |
2001年 | 9篇 |
2000年 | 6篇 |
1999年 | 16篇 |
1998年 | 14篇 |
1997年 | 11篇 |
1996年 | 12篇 |
1995年 | 9篇 |
1994年 | 8篇 |
1993年 | 5篇 |
1992年 | 2篇 |
1991年 | 2篇 |
1990年 | 3篇 |
1989年 | 5篇 |
1988年 | 4篇 |
1986年 | 6篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1981年 | 3篇 |
1980年 | 2篇 |
1963年 | 1篇 |
1946年 | 1篇 |
1940年 | 1篇 |
1938年 | 1篇 |
1923年 | 1篇 |
1911年 | 1篇 |
1907年 | 1篇 |
1905年 | 1篇 |
排序方式: 共有3611条查询结果,搜索用时 15 毫秒
11.
Triplett Noah S. Woodard Grace S. AlRasheed Rashed Meza Rosemary D. Robinson Sophia Berliner Lucy Dorsey Shannon 《The journal of behavioral health services & research》2021,48(4):617-624
The Journal of Behavioral Health Services & Research - Characterizing community mental health (CMH) treatment duration and discharge is an important step toward understanding how to better meet... 相似文献
12.
13.
Patrinos GP Garinis G Kounelis S Kouri E Menounos P 《Journal of molecular medicine (Berlin, Germany)》1999,77(9):686-689
We report a novel p53 deletion in a 63-year-old female with breast cancer. Mutation screening of DNA samples, obtained from tumor specimens from 98 individuals with breast cancer, by a combined polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis showed that the index case had a somatic mutation identified to be a 23-bp deletion in exon 5 of the p53 gene. This deletion would be expected to yield a truncated and functionally inactive p53 protein molecule, probably resulting in cell transformation. The existence of 6-bp palindromic-like sequences encompassing the deleted fragment suggests that the slipped mispairing mechanism is not involved in producing the deletion, which probably resulted from palindromic pairing during replication. 相似文献
14.
The process of regulated secretion in PC-12 cells is tightly coupled to calcium entry, which is absolutely dependent on extracellular Ca2+([Ca2+]ex). Tunicamycin treatment of the cells dissociated depolarization-triggered Ca2+ influx from depolarization (high K+)-induced transmitter release into two distinct and independent phases. Deplarization-evoked Ca2+ influx was not affected by tunicamycin treatment (1 microg/ml, 72 h), whereas depolarization-evoked transmitter release was strongly inhibited (> 60%), suggesting at least a two-step process, and the participation of glycosylated protein(s) in the actual fusion/secretion step. Similarly, bradykinin-mediated transmitter release was linearly related to and absolutely dependent on Ca2+ entry, and was inhibited by tunicamycin treatment (> 80%), whereas bradykinin-evoked Ca2+ entry was not impaired, indicating that glycosylated protein(s) are essential for bradykinin-evoked release at a step subsequent to Ca2+ influx. The heavily glycosylated alpha2 subunit of the dihydropyridine-sensitive channel, which was used to monitor tunicamycin inhibition of glycosylation, was not expressed in the tunicamycin-treated cells, as shown by Western blot analysis. This observation allowed us to conclude that the alpha1 subunit of the heteromeric dihydropyridine voltage-sensitive Ca2+ channel, which is responsible for Ca2+ entry, is also fully functional when not assembled with its corresponding alpha2 subunit. The molecular properties of the alpha2 subunit, whose role in the complex structure of the channel is not yet understood, are shown for the first time for the L-type Ca2+ channel of PC-12 cells. Similar to cardiac and skeletal muscle cells, the alpha2 subunit appears to be a glycosylated polypeptide of molecular weight 170 kD and to display a characteristic mobility shift to 140 kD under reducing conditions. 相似文献
15.
Raphael P Viscidi Mark Schiffman Allan Hildesheim Rolando Herrero Philip E Castle Maria C Bratti Ana Cecilia Rodriguez Mark E Sherman Sophia Wang Barbara Clayman Robert D Burk 《Cancer epidemiology, biomarkers & prevention》2004,13(2):324-327
Whether antibodies to human papillomavirus (HPV) capsids, elicited by natural infection, are protective is unknown. This question was addressed in a population-based cohort of 7046 women in Costa Rica by examining the association between baseline seroreactivity to HPV-16, HPV-18, or HPV-31 virus-like particles and the risk of subsequent HPV infection at a follow-up visit 5-7 years after enrollment. Seropositivity to HPV-16, HPV-18, or HPV-31 was not associated with a statistically significant decreased risk of infection with the homologous HPV type [relative risk (RR) and [95% confidence interval (CI)], 0.74 (0.45-1.2), 1.5 (0.83-2.7), and 0.94 (0.48-1.8), respectively]. Seropositivity to HPV-16 or HPV-31 was not associated with a decreased risk of infection with HPV-16 or its genetically related types [RR (95% CI), 0.82 (0.61-1.1) and 0.93 (0.68-1.2), respectively]. Seropositivity to HPV-18 was not associated with a decreased risk of infection with HPV-18 or its genetically related types (RR 1.3; 95% CI 1.0-1.8). Thus, we did not observe immunity, although a protective effect from natural infection cannot be excluded because of the limits of available assays and study designs. 相似文献
16.
Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. 总被引:1,自引:0,他引:1
Ramzi Dagher Ning Li Sophia Abraham Atiqur Rahman Raji Sridhara Richard Pazdur 《Clinical cancer research》2004,10(24):8147-8151
PURPOSE: Docetaxel, a taxane previously approved for the treatment of breast cancer and non-small cell lung cancer, was approved by the United States Food and Drug Administration on May 19, 2004 for use in combination with prednisone for the treatment of metastatic androgen-independent (hormone-refractory) prostate cancer. The purpose of this summary is to review the database supporting this approval. EXPERIMENTAL DESIGN: In a randomized, global study enrolling 1,006 patients, two schedules of docetaxel were compared with mitoxantrone + prednisone as follows: MTZ q 3w, mitoxantrone 12 mg/m2 every 21 days + prednisone 5 mg twice a day for a total of 10 cycles; TXT q 3w, docetaxel 75 mg/m2 every 21 days + prednisone 5 mg twice a day for a total of 10 cycles; and TXT qw, docetaxel 30 mg/m2 days 1, 8, 15, 22, and 29 every 6 weeks + prednisone 5 mg twice a day for a total of 5 cycles. RESULTS: There was a statistically significant overall survival advantage shown for the TXT q 3w arm over MTZ q 3w (median survival 18.9 months versus 16.5 months, P = 0.0094). No overall survival advantage was shown for TXT qw compared with MTZ q 3w. The most commonly occurring adverse events included anemia, neutropenia, infection, nausea, sensory neuropathy, fluid retention, alopecia, nail changes, diarrhea, and fatigue. CONCLUSIONS: This report describes the Food and Drug Administration review supporting this first approval of a combination therapy for hormone-refractory prostate cancer based on demonstration of a survival benefit. 相似文献
17.
Edvardas Kaminskas Ann Farrell Sophia Abraham Amy Baird Li-Shan Hsieh Shwu-Luan Lee John K Leighton Hasmukh Patel Atiqur Rahman Rajeshwara Sridhara Yong-Cheng Wang Richard Pazdur 《Clinical cancer research》2005,11(10):3604-3608
PURPOSE: This article summarizes data submitted to the U.S. Food and Drug Administration for marketing approval of azacitidine as injectable suspension (Vidaza, Pharmion Corporation, Boulder, CO) for treatment of patients with myelodysplastic syndrome. EXPERIMENTAL DESIGN: In one phase 3 controlled trial, 191 study subjects were randomized to treatment with azacitidine or to observation; an additional 120 patients were treated with azacitidine in two phase 2 single arm studies. The primary efficacy end point was the overall response rate, defined as complete or partial normalization of peripheral blood counts and bone marrow blast percentages for at least 4 weeks. RESULTS: In the controlled trial, the overall response rate was 15.7% in the azacitidine treatment group; there were no responders in the observation group (P < 0.0001). Response rates were similar in the two single arm studies. During response patients stopped being red cell or platelet transfusion dependent. Median duration of responses was at least 9 months. An additional 19% of azacitidine-treated patients had less than partial responses, most becoming transfusion independent. The most common adverse events attributed to azacitidine were gastrointestinal, hematologic, local (injection site), and constitutional. There were no azacitidine-related deaths. CONCLUSIONS: On May 19, 2004 the U.S. Food and Drug Administration approved azacitidine as injectable suspension for treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia. Full prescribing information is available at http://www.fda.gov/cder/foi/label/2004/050794lbl.pdf. Azacitidine is the first agent approved for treatment of myelodysplastic syndrome. 相似文献
18.
19.
20.